Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Browse by Current Cardiff authors

Number of items: 8.

Zabkiewicz, Joanna ORCID:, Lazenby, Michelle, Edwards, Gareth, Bygrave, Ceri A., Omidvar, Nader, Zhuang, Lihui, Knapper, Steve ORCID:, Guy, Carol, Hills, Robert K. ORCID:, Burnett, Alan K. and Alvares, Caroline L. ORCID: 2020. Combination of a mitogen‐activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion‐based residual disease and prevents re‐expansion of FLT3 ‐ITD acute myeloid leukaemia. British Journal of Haematology 191 (2) , pp. 231-242. 10.1111/bjh.16665

Lazenby, Michelle 2019. Characterisation of extracellular vesicles from the microenvironment in high risk acute myeloid leukaemia. MPhil Thesis, Cardiff University.
Item availability restricted.

Lazenby, M., Hills, R. ORCID:, Burnett, A. K. and Zabkiewicz, J. ORCID: 2015. The HSP90 inhibitor ganetespib: a potential effective agent for Acute Myeloid Leukemia in combination with cytarabine. Leukemia Research 39 (6) , pp. 617-624. 10.1016/j.leukres.2015.03.016

Ostronoff, F., Othus, M., Lazenby, Michelle, Estey, E., Appelbaum, F. R., Evans, Anna ORCID:, Godwin, J., Gilkes, Amanda F., Kopecky, K. J., Burnett, Alan, List, A. F., Fang, M., Oehler, V. G., Petersdorf, S. H., Pogosova-Agadjanyan, E. L., Radich, J. P., Willman, C. L., Meshinchi, S. and Stirewalt, D. L. 2015. Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: A SWOG and UK National Cancer Research Institute/Medical Research Council report. Journal of Clinical Oncology 33 (10) , pp. 1157-1164. 10.1200/JCO.2014.58.0571

Lazenby, Michelle, Gilkes, Amanda, Marrin, C., Evans, Anna ORCID:, Hills, Robert Kerrin ORCID: and Burnett, A. K. 2014. The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial. Leukemia 28 , pp. 1953-1959. 10.1038/leu.2014.90

Walsby, Elisabeth Jane ORCID:, Lazenby, Michelle, Pepper, Christopher John, Knapper, Steven ORCID: and Burnett, Alan Kenneth 2013. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells. British Journal of Haematology 161 (1) , pp. 57-67. 10.1111/bjh.12215

Walsby, Elisabeth Jane ORCID:, Lazenby, Michelle, Pepper, Christopher John and Burnett, Alan Kenneth 2011. The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine. Leukemia 25 (3) , pp. 411-419. 10.1038/leu.2010.290

Gale, Rosemary, Hills, Robert Kerrin ORCID:, Green, Claire, Patel, Yashma, Gilkes, Amanda F., Lazenby, Michelle, Wheatley, Keith, Linch, David C. and Burnett, Alan Kenneth 2008. The impact of FLT3-ITD and NPM1 Mutational Status on the outcome of ATRA therapy in patients with Non-APL AML: results of the UK MRC AML12 trial [Abstract]. Blood -New York- 112 (11) , p. 207.

This list was generated on Sat May 18 06:37:21 2024 BST.